Vancomycin Administration<\/p>\n
Student\u2019s Name <\/p>\n
University<\/p>\n
Course<\/p>\n
Professor<\/p>\n
Date<\/p>\n
Vancomycin administration<\/p>\n
BA is a 66year female admitted to the inpatient department for intravenous antibiotics, wound debridement, and management of his right great toe. She has past cellulitis ulcers, which complicated with wound culture positive for MRSA<\/p>\n
The subjective data:<\/p>\n
The patient stepped on an exposed carpet tack while walking two months ago at his home, which caused a cut at his right toe. She reports that the area has never healed fully, and the wound seems to be getting bigger. She reports that there has been increased redness and fowl whitish-yellow discharge on his socks over the past week. She complains of fever, chills, and sweats over several days. She has been on ibuprofen for the pain without any relief. The patient reports not self-monitoring her blood glucose levels often at home. She reports no known allergies. <\/p>\n
She denies weight loss, weakness, or fatigue on a systematic review. Regarding the HEENT system, she denies visual loss or changes, and no signs of upper respiratory tract infection are reported. She denies chest pain, discomfort, and pressure on the cardiovascular system review. Respiratory-wise, no signs of DIB or lower respiratory tract infection. She is a known diabetic and hypertensive patient taking lisinopril 5mg once a day and metformin 850mg twice a day. <\/p>\n
Socially, she is a retired teacher who lives with her husband. She quit smoking 32years ago and denies consuming alcohol. she is very active in the community and would like to resume her driving after going back to her volunteer work<\/p>\n
Objective data<\/p>\n
No distress was noted on observation. The patient is communicating and comprehending verbal instructions. On taking vitals, the patient is stable with a temperature of 101f, pulse rate of 93b.p.m, respiratory rate of 19b.p.m, and blood pressure of 123\/70mm\/hg. She weighs 13Olbs. On auscultation, there are scattered expiratory wheezes. s1 and s2 of the heart record regular rate and rhythm. On palpation, the abdomen is soft and non-tender. Bowel sounds were noted four times. The extremities are bilateral with one pitting edema. A 3cm necrotic concentric wound on the plantar surface of the right hallux, first metatarsal head. Local wound symptoms were noted, including cellulitis. Black Escher noted around edges with a soft yellow appearance towards the center of the wound. The wound produces a moderate amount of creamy yellow purulent exudate.<\/p>\n
An x-ray of the right foot shows minimal soft tissue swelling on the dorsum of the foot. Question of mild cortical irregularity at first MTP joint .more investigations are pending to confirm the diagnosis. An MRI done confirms osteo edema and osteomyelitis. Concerning the lab works, no indication of signs of AKI. The goal of treatment on osteomyelitis is to eradicate the infection <\/p>\n
while preserving the soft tissue, healing the bone segment, and preserving the length function of the limb<\/p>\n
Assessment<\/p>\n
A: IBW(ideal body weight)<\/p>\n
Patient height 5feet 3inches<\/p>\n
IBW=45.5+2.3(each inch over 5feet)<\/p>\n
=45.5+2.3(3)<\/p>\n
=45.5+6.9<\/p>\n
=52.4kgs<\/p>\n
B: choice of body weight this is the adjusted body weight<\/p>\n
ADJBW=IBW+0.4*(ABW-IBW)<\/p>\n
ABW=130Pounds<\/p>\n
1pound=0.454<\/p>\n
130pounds=?<\/p>\n
130*0.454\/1<\/p>\n
=59.02kgs<\/p>\n
ADJBW=52.4+0.4*(59.02-52.4)<\/p>\n
=52.4+0.4*(6.62)<\/p>\n
=52.4+2.648<\/p>\n
=55.048<\/p>\n
C: creatinine clearance(CrCl)<\/p>\n
CrCl=[114-(0.8*age)]\/creatinine level In mg\/dl<\/p>\n
=[114-(0.8*66)]\/1.9<\/p>\n
=[114-52.8]\/1.9<\/p>\n
=61.2\/1.9<\/p>\n
=32.21<\/p>\n
D:ke<\/p>\n
=0.00083*CrCl+0.0044<\/p>\n
=0.00083*32.21+0.0044<\/p>\n
=0.0267+0.0044<\/p>\n
=0.0311<\/p>\n
E:half life(T1\/2)<\/p>\n
=0.693\/Ke=0.693\/0.0311<\/p>\n
=22.28<\/p>\n
F_Tau=6*{72\/[(10*cl)+1.9]}<\/p>\n
CL=(CrCl*0.0075)+0.004<\/p>\n
=(32.21*0.0075)+0.004<\/p>\n
=0.2416+0.04<\/p>\n
CL=0.2816<\/p>\n
Tau=6*{72\/[(10*0.2816)+1.9]}<\/p>\n
=6*{72\/[2.816+1.9]<\/p>\n
=6*{72\/4.716}<\/p>\n
=6*15.2672<\/p>\n
=91.6032<\/p>\n
G: loading dose<\/p>\n
a) standard loading dose<\/p>\n
25-30mg\/kg<\/p>\n
=25*52.4<\/p>\n
=1310mgs<\/p>\n
Approximately 1500mgs<\/p>\n
30*52.4<\/p>\n
=1572<\/p>\n
Approximately 1750mgs<\/p>\n
b) modified loading dose<\/p>\n
Applies when CrCl is less than 30 and no signs of AKI, plus the patient shouldn\u2019t be on CRRT<\/p>\n
20-25mg\/kg<\/p>\n
=20*52.4<\/p>\n
=1048mgs<\/p>\n
Approximately 1250mgs<\/p>\n
25*52.4<\/p>\n
=1310mgs<\/p>\n
Approximately 1500mgs<\/p>\n
H: maintenance dose<\/p>\n
For CrCl of (30-50), dose of 10-15mg\/kg<\/p>\n
10*52.4<\/p>\n
=524mgs<\/p>\n
Approximately 750mgs <\/p>\n
Or<\/p>\n
15*52.4<\/p>\n
=786<\/p>\n
Approximately 1000mgs<\/p>\n
I: expected trough and peak concentrations for maintenance doses<\/p>\n
The expected peak is an hour after the 3rd dose<\/p>\n
The expected trough is 30mins before 3rd dose<\/p>\n
The infusion rate is two to three doses daily within the standard rate. One gram runs over 60mins. The standard infusion rate is important to prevent erythematous rash on the upper body and face. Vancomycin is intravenous as it has low oral bioavailability. Treatment is given for a period between 7 days and 21 days. Vancomycin causes nephrotoxicity; hence close monitoring is essential.<\/p>\n","protected":false},"excerpt":{"rendered":"
Vancomycin Administration Student\u2019s Name University Course Professor Date Vancomycin administration BA is a 66year female admitted to the inpatient department<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-42721","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\n